Burden of proof: Breast cancer changes fall short

Key points
- Making drastic changes to U.S. breast cancer screening guidelines will take much stronger evidence than that offered by a federal advisory panel this week, U.S. doctors said on Friday.
- Preventive Services Task Force recommendation advising against routine mammograms for women in their 40s was a gamble many doctors are not willing to take.
- The recommendations to scale back breast cancer screening touched off a fierce backlash from physicians and an outcry from women, forcing U.S.
- Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, rejects the notion offered by some Republican politicians that the guidelines are motivated by a push to ration healthcare.
Making drastic changes to U.S. breast cancer screening guidelines will take much stronger evidence than that offered by a federal advisory panel this week, U.S. doctors said on Friday.
They said the U.S. Preventive Services Task Force recommendation advising against routine mammograms for women in their 40s was a gamble many doctors are not willing to take.
The recommendations to scale back breast cancer screening touched off a fierce backlash from physicians and an outcry from women, forcing U.S. Health and Human Services Secretary Kathleen Sebelius to renounce the guidelines and assure women they did not reflect U.S. policy.
Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, rejects the notion offered by some Republican politicians that the guidelines are motivated by a push to ration healthcare.
But he said such decisions need to be based on strong evidence, especially when evidence is conflicting.
"Here we have a strategy that has been in place for 20 years and it's worked. The task force is coming in and saying, 'Forget the fact that it worked. We think this is the right way.' If the science was strong, we would agree with it," Lichtenfeld said.
"If they are right, no problem. But if they are wrong, we won't find out for 20 years. That is the risk," he said.
Instead of an annual mammogram starting at 40, the new guidelines call for routine screening to start at age 50 for women of average risk, and say they should been done every other year instead of yearly to balance the harms of false positive results with the benefits of saving lives.
They also recommend against teaching women to do self breast exams, because they say the evidence is not strong enough to show the practice saves lives.
QUESTIONING MODELS
One obvious concern is whether women might die of breast cancer because of the recommendations, said Dr. Thomas Herzog of Columbia University in New York, chairman of an American College of Obstetricians and Gynecologists subcommittee on gynecologic cancers.
He and others also questioned the task force's heavy reliance on computer models instead of real-life data.
"I guess the problem, if anything, that people have is this is based on theory," Herzog said in a telephone interview.
"It may be excellent theory. It may be the best theory out there, but nonetheless, it's not prospective data that says how these new guidelines are actually going to perform," he added.
"We will only know looking back if these guidelines did their job."
Both the American Cancer Society and the American College of Obstetricians and Gynecologists stand by their current recommendations for screening mammograms to start at age 40.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNonrecommended screenings for prostate, breast cancer in older individuals
An estimated 15.7 percent of individuals 65 or older may have received nonrecommended screenings for prostate and breast cancers because they had limited life expectancies of less than 10 years, according to an article…
22 January 2016
GuideNew method for better treatment of breast cancer
A new study shows that a novel imaging-based method for defining appropriateness of breast cancer treatment is as accurate as the current standard-of-care and could reduce the need for invasive tissue sampling. The…
31 December 2015
NewsT cells that recognize HER2 teceptor may prevent HER2+ breast cancer recurrence
Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient's immune system - a weakness that in principle could be corrected with a…


